February 09, 2026 | Tübingen, Germany
PRESS RELEASE
Capnopharm expands its R&D and administrative facilities in Tübingen
CapnoPharm, an innovative company focused on advancing drug delivery technologies and pharmaceutical development, announces the expansion of its research and development as well as administrative facilities in Tübingen. This strategic growth reflects CapnoPharm’s commitment to strengthening its capabilities in engineering, pharmaceutical sciences, and translational medicine.
Over the past months, CapnoPharm has significantly reinforced its R&D team, now comprising development and quality engineers, pharmacists, biochemists, and physicians. This multidisciplinary expertise positions the company to accelerate innovation and ensure the highest standards in product development and validation.
To support these growing activities and provide optimal working conditions for its expanding workforce, CapnoPharm has rented additional administrative office space starting in January 2026.
In February 2026, the company is further extending its R&D laboratory infrastructure. The expanded facilities now include:
- An Engineering Laboratory dedicated to prototyping and technical development.
- A Biophysics Laboratory for verification and validation (V&V), equipped with laser diffraction spectrometry and advanced optical imaging systems for both PIPAC and ePIPAC applications.
- A Pharmaceutical Laboratory featuring rheometry, a high-pressure reactor for nano-emulsion development, HPLC analytics, and lyophilization capabilities.
- A Biology Laboratory supporting cell culture, automated cell counting, robotized 3D multichannel fluorescence microscopy, and functional assays performed in vitro and ex vivo.
“These expansions represent a further milestone for CapnoPharm,” said Dr. Hans Schönfelder CapnoPharm’s CSO. “By investing in state-of-the-art laboratories and strengthening our scientific and engineering teams, we are creating the foundation for the next phase of innovation and growth.”
The official inauguration of the expanded facilities is scheduled for February 26th, 2026, in Tübingen.
ABOUT Capnopharm
CapnoPharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC provides numerous avenues for research and development in oncology — from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug–device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
For more information, please contact :
S. Laurent, Chief Commercial Officer at: s.laurent@capnopharm.com
The CapnoPen® is a registered Trademark of CapnoPharm GmbH, Tübingen, Germany.
November 15, 2025 | Tübingen, Germany
PRESS RELEASE
Capnopharm SECURES EUROPEAN PATENT FOR NANO-EMULSION CHEMOTHERAPY TECHNOLOGY ENABLING INTRACAVITARY AEROSOL DELIVERY
CapnoPharm GmbH today announced the granting of its European Patent EP 3 669 863 B1, covering the company’s groundbreaking technology for micro and nano-emulsions of chemotherapeutic agents designed for intracavitary delivery as an aerosol. This patent marks a significant milestone in CapnoPharm’s evolution from a leading manufacturer of medical devices to a provider of comprehensive diagnostic and therapeutic solutions for patients with peritoneal cancer.
The newly granted patent protects a broad platform of nano-emulsion formulations, including a wide range of approved chemotherapeutic drugs — such as cisplatin, doxorubicin, paclitaxel, and oxaliplatin— reformulated into highly stable oil-in-water nano-emulsions. These formulations are engineered explicitly for intraperitoneal application, including delivery through Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC).
A Foundational Technology for Future Pharma Products
The patented technology is designed to improve penetration, stability, and tissue retention of chemotherapeutic agents within the peritoneal cavity. Nano-emulsions enable enhanced permeation through biological barriers such as the peritoneum while maintaining lower systemic exposure. This is particularly important in the treatment of peritoneal metastasis, where conventional systemic chemotherapy often fails to cross the blood-peritoneum barrier.
This patent establishes the scientific and regulatory foundation for CapnoPharm’s proprietary pharmaceutical formulations, which are currently under development. These formulations are expected to play a central role in the future approval pathway for new aerosol chemotherapies tailored for peritoneal cancer.
“The granting of our European patent confirms the novelty and the therapeutic potential of our nano-emulsion platform,” said H. Schönfelder, PhD., Chief Scientific Officer at CapnoPharm. “It reinforces our long-term strategy of bridging medical devices and pharmaceutical innovation to shape the future of intraperitoneal cancer care.”
Strengthening CapnoPharm’s Leadership in PIPAC Innovation
For over a decade, CapnoPharm’s team has been at the forefront of pioneering PIPAC and advancing the science of medical aerosols for oncology. With this patent, the company expands its protection beyond devices such as the CapnoPen® nebulizer into the realm of pharmaceutical formulations —paving the way toward complete therapeutic ecosystems combining:
- advanced aerosol drug delivery devices,
- proprietary nano-emulsion chemotherapy, and
- translational research partnerships across the biotech and oncology landscape.
This strategic expansion supports CapnoPharm’s broader mission to deliver integrated solutions that enhance treatment outcomes and improve the quality of life for patients affected by peritoneal metastasis.
ABOUT Capnopharm
CapnoPharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC provides numerous avenues for research and development in oncology — from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug–device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
For more information, please contact :
S. Laurent, Chief Commercial Officer at: s.laurent@capnopharm.com
The CapnoPen® is a registered Trademark of CapnoPharm GmbH, Tübingen, Germany.
November 15, 2025 | Tübingen, Germany
PRESS RELEASE
CapnoPharm GmbH announces that the Civil Court of Rottweil (Landgericht Rottweil) has issued a final and legally binding judgment in case 4 O 47/22. As no appeal was filed, the decision is now legally binding. The Court confirms that Prof. Marc A. Reymond, CEO of CapnoPharm, is the sole legal owner of the patents listed in the judgment as of 1 January 2022.
The Court ordered Mr. Alexander Hetzel, CEO of Reger Medizintechnik GmbH, to transfer to Prof. Reymond all patents and patent applications identified in the ruling. These include fourteen patents related to the CapnoPen® CP–001 technology and CapnoPharm’s multinozzle aerosol technology. Furthermore, the Court required Mr. Hetzel to bear the full costs of the legal proceedings.
Court Ruling Establishes Clear Patent Ownership
This judgment marks a significant milestone for CapnoPharm. The consolidation of these patents significantly strengthens the company’s intellectual property position in the global PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) landscape. The patent portfolio encompasses core aerosol drug-delivery mechanisms and essential device technologies central to CapnoPharm’s proprietary innovations.
“This final judgment provides legal clarity and reinforces the strength of Capnopharm’s innovation strategy,” said Prof. Marc A. Reymond, CEO of CapnoPharm and inventor of PIPAC. “We welcome the Court’s decision and remain committed to advancing safe, effective, and cutting-edge aerosol chemotherapy technologies for the benefit of patients.”
Court Decision Consolidates CapnoPharm’s Leadership in PIPAC Innovation
With this legally confirmed patent ownership, CapnoPharm is well-positioned to accelerate the development of next-generation device technologies and pharmaceutical nano-aerosol formulations. The ruling supports CapnoPharm’s strategic evolution from a medical device manufacturer to a provider of fully integrated drug–device solutions for peritoneal metastasis.”
ABOUT Capnopharm
CapnoPharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC provides numerous avenues for research and development in oncology — from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug–device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
For more information, please contact :
S. Laurent, Chief Commercial Officer at: s.laurent@capnopharm.com
The CapnoPen® is a registered Trademark of CapnoPharm GmbH, Tübingen, Germany.
July 15, 2025 | Tübingen, Germany
PRESS RELEASE
PIPAC Recognized in German Occupational Safety Guidelines in Oncology
The inclusion of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the latest edition of Germany’s workers’ insurance prevention manual marks a major step forward in the institutional recognition of this innovative cancer therapy. The manual, a national reference for handling cytotoxic drugs safely, offers official guidance to healthcare professionals across Germany.
Published by the Berufsgenossenschaften (BGs), Germany’s statutory accident insurance institutions under Social Code Book VII (SGB VII), the manual plays a central role in preventing work-related illness and ensuring safe clinical practices. The addition of PIPAC reflects its integration into national occupational health standards and reinforces the need for standardized protective measures during its use.
The manual places PIPAC alongside recognized procedures like HIPEC and transarterial chemoembolization, providing specific recommendations for personal protective equipment (PPE) based on exposure risk. This institutional endorsement confirms PIPAC’s maturity and strengthens its clinical legitimacy.
Prof. Reymond, PIPAC’s inventor and CapnoPharm’s CEO, stated: “To see PIPAC included in such a respected national guideline highlights the progress we’ve made — and the responsibility we carry to uphold the highest standards of safety and efficacy. This milestone belongs to the entire PIPAC community.”
ABOUT Capnopharm
CapnoPharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC provides numerous avenues for research and development in oncology — from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug–device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
For more information, please contact :
S. Laurent, Chief Commercial Officer at: s.laurent@capnopharm.com
The CapnoPen® is a registered Trademark of CapnoPharm GmbH, Tübingen, Germany.
March 21, 2025 | Tübingen, Germany
Capnopharm GMBH Awarded European Commission’s Seal of Excellence
for Groundbreaking Peritoneal Cancer Therapy
CapnoPharm is proud to announce that the European Commission has awarded it the prestigious Seal of Excellence for its pioneering project focused on developing, validating, and commercializing a novel drug-device combination therapy for peritoneal cancer.
The Seal of Excellence is a mark of high quality awarded to proposals submitted under the Horizon Europe EIC call that meet the rigorous evaluation standards but could not be funded due to budgetary limitations. CapnoPharm’s project was recognized for its strong potential to deliver a transformative impact on cancer treatment.
“We are honored to receive this recognition from the European Commission,” said Prof. Marc Reymond, CapnoPharm‘s CEO. “This endorsement underscores the innovative strength of our approach and reinforces our mission to advance effective new therapies for peritoneal cancer.”
Dr. Hans Schönfelder, Chief Scientific Officer at CapnoPharm added, “This award validates our technology’s scientific and therapeutic value. We are confident that our work will bring meaningful patient benefits and help reshape the future of peritoneal cancer care.”
The Seal of Excellence includes a unique digital certificate, acknowledging the proposal’s scientific merit and credibility. It also enhances CapnoPharm‘s visibility and facilitates access to alternative funding from national, regional, or EU-level sources, paving the way for continued progress on this promising project.
ABOUT Capnopharm
CapnoPharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC provides numerous avenues for research and development in oncology — from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug–device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
For more information, please contact :
S. Laurent, Chief Commercial Officer at: s.laurent@capnopharm.com
The CapnoPen® is a registered Trademark of CapnoPharm GmbH, Tübingen, Germany.
April 03, 2024 | Tübingen, Germany
Press Release
PIPAC, the Pressurized IntraPeritoneal Aerosol Chemotherapy acronym, was invented by CapnoPharm’s chairman, Prof. Marc Reymond, in 2014. Ten years later, the abbreviations “PIPAC” and “PITAC” are widely accepted in the community and have been used in over 300 peer-reviewed publications. PIPAC and PITAC are also CapnoPharm’s proprietary brands in Europe, the USA, and numerous other countries.
CapnoPharm wishes to facilitate PIPAC’s development and to contribute to an ethical business. Thus, CapnoPharm has now decided to waive its proprietary rights to the PIPAC™ and PITAC brands, making these acronyms freely available to physicians, hospitals, and all other stakeholders. We are confident that this move will find appropriate recognition in the community.
We hope that our move will boost the development of PIPAC and PITAC in the interest of patients with peritoneal metastases.
ABOUT CAPNOPHARM
CapnoPharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC provides numerous avenues for research and development in oncology — from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug–device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
For more information, please contact :
S. Laurent, Chief Commercial Officer at: s.laurent@capnopharm.com
The CapnoPen® is a registered Trademark of CapnoPharm GmbH, Tübingen, Germany.
November 15th, 2023 | Tübingen, Germany
Press Release
CapnoPharm is the winner of the German Medical Award 2023. Our company was recognized as the most innovative medical Start-Up in Germany amongst 800 contestants. This victory confirms Capnopharm’s leadership and highlights PIPAC’s disruptive power at the crossroads of pharma, engineering, and peritoneal medicine.
Prof. Marc Reymond, MD MBA, and Ranjita Sahoo, PhD, received the prize in person at an award ceremony held in Dusseldorf, Germany, on 15th November 2023, in the presence of Karl-Josef Laumann, Minister for Labor, Health and Social Affairs.
Concentrating on patient-oriented care, The German Medical Award is the leading and only medicine and medical management award in Germany, Austria and Switzerland. This award acknowledges outstanding performance and innovations in medicine with a focus on interdisciplinary, medical, technical, and pharmaceutical care solutions.
ABOUT CAPNOPHARM
CapnoPharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC provides numerous avenues for research and development in oncology — from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug–device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
For more information, please contact :
S. Laurent, Chief Commercial Officer at: s.laurent@capnopharm.com
The CapnoPen® is a registered Trademark of CapnoPharm GmbH, Tübingen, Germany.
June 20th, 2023 | Tübingen, Germany
Press Release
CapnoPharm is proud to announce that the company has been awarded today with the seal of the Certification Body for Research Grants (BSFZ). BSFZ is part of the German Federal Ministry of Education and Research. The BFSZ seal is awarded exclusively to small and medium enterprises (SME) that are entitled to claim funding from research grants, after a thorough independent audit. The BSFZ seal confirms that CapnoPharm’s R&D projects are original, novel and attractive. Although CapnoPharm projects are ambitious, they have been considered by the experts to be budgetable, systematic, transferable, and reproducible.
Dr. Ranjita Sahoo, CapnoPharm’s Chief Scientific Officer, is delighted about this recognition: “CapnoPharm was a Winner of the German Innovation Award in 2022. The BSFZ seal is further proof of Capnopharm’s innovation potential. This seal will ease CapnoPharm’s access to national and international innovation grants in the future.” Stéphane Laurent, CapnoPharm’s Vice President for Global Sales & Business Development, adds: “CapnoPharm is recognized as a pioneer of loco-regional drug delivery as aerosols worldwide. Our R&D pipeline, including new devices and drug-device combinations, will strengthen this leadership, fuel our revenue streams and enable CapnoPharm’s access to a large and emerging PIPAC market”.
ABOUT CAPNOPHARM
CapnoPharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC provides numerous avenues for research and development in oncology — from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug–device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
For more information, please contact :
S. Laurent, Chief Commercial Officer at: s.laurent@capnopharm.com
The CapnoPen® is a registered Trademark of CapnoPharm GmbH, Tübingen, Germany.
June 12th, 2023 | Tübingen, Germany
Press Release
CapnoPharm GmbH is pleased to announce that the company has received certification of its quality system to the ISO 13485:2016 standard. This ISO certification documents that the company’s quality management system adheres to the most current regulatory requirements specific to the medical device industry. This International Standard, through the implementation of a quality management system, complements the technical requirements for a product to ensure its safety, regulatory compliance, and performance.
“We are proud of receiving this certification recognizing the commitment of our team to quality, and to the highest customer’s and international regulatory expectations”, said Dr. Kristijana Milovic-Holm, Head of Quality Management and Regulatory Affairs at CapnoPharm. “We are dedicated to continuously improving the quality of our products, processes, and services to ensure patient safety and to meet future market access requirements”.
Prof. Marc Reymond, CapnoPharm’s CEO, adds: “At CapnoPharm, we strive to achieve the highest standards in terms of innovation and quality. The ISO 13485:2016 certification is a collective achievement of all of our employees. We want to send a clear message to patients and physicians, positioning our company as a trustworthy and reliable supplier”.
The ISO 13485:2016 standard is based on ISO 9001:2008 and specifies the requirements an organization needs to demonstrate in providing one or more stages of the life-cycle of a medical device, which includes the design, development, production, storage, distribution, installation, and servicing of a medical device.
ABOUT CAPNOPHARM
CapnoPharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC provides numerous avenues for research and development in oncology — from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug–device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
For more information, please contact :
S. Laurent, Chief Commercial Officer at: s.laurent@capnopharm.com
The CapnoPen® is a registered Trademark of CapnoPharm GmbH, Tübingen, Germany.
Press Release
CapnoPharm is proud to announce that its new CapnoPen® CP-001k received CE certification (MDR) for aerosolizing chemotherapy, DNA, RNA, nanomolecules, viruses, and immunotherapy into body cavities. As the only nebulizer with such certification, the new CapnoPen® is setting a new regulatory standard in Intraperitoneal Chemotherapy.
Stéphane Rohan Laurent, CapnoPharm’s VP Sales & Business Development, comments: “Receiving CE certification constitutes a landmark achievement for our new CapnoPen® technology. It also responds to the growing demand from the oncology community for durable, harmonized standards in Intraperitoneal Chemotherapy.”
CapnoPharm’s new CapnoPen® is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745. Prof. Marc Reymond, CapnoPharm’s CEO, sees here a benefit for the patients and their physicians: “CapnoPharm’s new CapnoPen® is approved for its effective intended use, namely aerosolizing chemotherapy, DNA, RNA, nanomolecules, viruses, and immunotherapy into body cavities. This is in contrast to other nebulizers on the market which are only approved for aerosolizing aqueous solutions or for irrigating the abdominal cavity: in clinical practice, these nebulizers are used “off-label”. The new CapnoPen® is now classified into the appropriate risk category. Its regulatory approval meets the most current MDR standards and is the result of a thorough technical, biological, and clinical evaluation. This evaluation and the resulting approval protect the interests of patients and healthcare practitioners alike”.
ABOUT CAPNOPHARM
CapnoPharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC provides numerous avenues for research and development in oncology — from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug–device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
For more information, please contact :
S. Laurent, Chief Commercial Officer at: s.laurent@capnopharm.com
The CapnoPen® is a registered Trademark of CapnoPharm GmbH, Tübingen, Germany.
August 18th, 2022
Press Release
CapnoPharm is proud to announce its selection as Finalist of the prestigious Reuters Pharma Europe Award 2022 for its Cancer drug delivery innovation – Capnodrug® – in the Health Entrepreneur Award category. CapnoPharm was shortlisted out of a pool of 800 applicants, including some of the world’s leading pharmaceutical companies, and is eagerly awaiting the awards ceremony in London on 17th November 2022.
Each year, over one million patients worldwide are diagnosed with peritoneal cancer – a condition often consecutive to stomach, bowel or gynecological cancer. For most patients, there is no truly effective therapy. Systemic chemotherapy is less effective than in other indications. There is no chemotherapeutic drug approved for intraperitoneal drug delivery.
The awarded CapnoDrug® technology is a patented drug delivery platform with several benefits against peritoneal cancer : homogenous distribution of the drug within the abdominal cavity, direct access to the tumor site, sustained drug release and enhanced delivery to the tumor cells. CapnoDrug® can also be used for non-viral and viral gene delivery.
In May 2022, CapnoPharm was already an acclaimed winner of the German Innovation Awards in the Medical Technologies Category. Reaching the finals of the Pharma Europe Award 2022 marks the sixth award achievement for CapnoPharm and its sister company Capnomed since 2020.
CapnoPharm is committed to advancing peritoneal cancer care and improving the health and well-being of patients around the world – for the greatest possible quality of life.
For more on Pharma Awards Europe 2022 please visit.
https://events.reutersevents.com/pharma/awards-europe.
Please visit www.capnopharm.com
ABOUT CAPNOPHARM
CapnoPharm is a global medical technology company focusing on the development of innovative processes involving medical aerosols. Our science relies on a growing body of evidence around PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. PIPAC provides numerous avenues for research and development in oncology — from the reformulation of approved chemotherapy drugs to next-generation drugs involving nanoparticles, siDNA, mRNA, oncolytic viruses, immunotherapeutics, and cellular therapies. Together with our pharmaceutical clients, we explore the drug–device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.
For more information, please contact :
S. Laurent, Chief Commercial Officer at: s.laurent@capnopharm.com